Antibody-drug conjugates as targeted cancer therapeutics

Yaoxue Xuebao

Volumn 44, Issue 9, 2009, Pages 943-952

  Sun, Yu ^a,b   Yu, Fei ^a   Sun, Bai Wang ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Antibody drug conjugate; Component; Internalization; Targeted cancer therapeutics

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; AURISTATIN PHENYLALANINE PHENYLENEDIAMINE; BEVACIZUMAB; C242 ANTIBODY MAYTANSINOID CONJUGATE; CALICHEAMICIN; CD138 ANTIBODY MAYTANSINOID CONJUGATE; CD20 ANTIBODY CALICHEAMICIN CONJUGATE; CD30 ANTIBODY AURISTATIN CONJUGATE; CD56 ANTIBODY MAYTANSINOID CONJUGATE; CD70 ANTIBODY AURISTATIN CONJUGATE; CD79 ANTIBODY AURISTATIN CONJUGATE; CETUXIMAB; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; LEWIS ANTIBODY CALICHEAMICIN CONJUGATE; MAYTANSINE; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN E; MONOMETHYL AURISTATIN F; MUC1 ANTIBODY CALICHEAMICIN CONJUGATE; MUC16 THIOMAB ANTIBODY AURISTATIN CONJUGATE; N ACETYL GAMMA CALICHEAMICIN DIMETHYL ACID; N ACETYL GAMMA CALICHEAMICIN DIMETHYLHYDRAZIDE; N2 DEACETYL N2 (3 MERCAPTO 1 OXOPENTYL) MAYTANSINE; N2 DEACETYL N2 (4 MERCAPTO 4 METHYL 1 OXOPROPYL) MAYTANSINE; PANITUMUMAB; RITUXIMAB; SOBLIDOTIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CAVEOLA; COLORECTAL CANCER; CYTOTOXICITY; DRUG ACTIVATION; DRUG CONJUGATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; IC 50; INTERNALIZATION; KIDNEY CARCINOMA; LEWIS CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY TUMOR; PINOCYTOSIS; REVIEW; TARGET CELL DESTRUCTION; TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; IMMUNOTOXINS;

EID: 71049117714     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Jaracz S, Chen J, Kuznetsova LV, et al. Recent advances in tumor-targeting anticancer drug conjugates [J]. Bioorg Med Chem, 2005, 13: 5043-5054. (Pubitemid 41039965)
2. Zhao J, Cao SL, Zheng XL, et al. Folate receptor-mediated antitumor drugs [J]. Acta Pharm Sin, 2009, 44: 109-114.
3. Moolten FL, Cooperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells [J]. Science, 1970, 169: 68-70.
4. Dai Y, Liu XJ, Zhen YS. Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody [J]. Acta Pharm Sin, 2006, 41: 41-46.
5. Burke PJ, Toki BE, Meyer DW, et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl- amine linker system [J]. Bioorg Med Chem Lett, 2009, 19: 2650-2653.
6. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia [J]. Clin Cancer Res, 2001, 7: 1490-1496. (Pubitemid 32708610)
7. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates [J]. J Biol Chem, 2006, 281: 10540-10547.
8. Jeffrey SC, Nguyen MT, Andreyka JB, et al. Dipeptide-based highly potent doxorubicin antibody conjugates [J]. Bioorg Med Chem Lett, 2006, 16: 358-362.
9. Smith LM, Nesterova A, Alley SC, et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97 [J]. Mol Cancer Ther, 2006, 5: 1474-1482. (Pubitemid 44070484)
10. Poison AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma [J]. Blood, 2007, 110: 616-623.
11. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics [J]. Nat Rev Drug Discov, 2006, 5: 147-159.
12. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates [J]. Cancer Res, 2006, 66: 2328-2337.
13. DiJoseph JF, Dougher MM, Armellino DC, et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab [J]. Cancer Immunol Immunother, 2007, 56: 1107-1117.
14. Law CL, Cerveny CG, Gordon KA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates [J]. Clin Cancer Res, 2004, 10: 7842-7851.
15. Jedema I, Barge RM, van der Velden VH, et al. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity [J]. Leukemia, 2004, 18: 316-325. (Pubitemid 38240048)
16. Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a humanmultiplemyeloma xenograft and in monkeys [J]. Clin Cancer Res, 2005, 11: 5257-5264. (Pubitemid 41003714)
17. Ojima I, Geng XD, Wu XY, et al. Tumor-specific novel taxoid-monoclonal antibody conjugates [J]. J Med Chem, 2002, 45: 5620-5623. (Pubitemid 35453753)
18. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs [J]. Acc Chem Res, 2008, 41: 98-107.
19. Hollander I, Kunz A, Hammann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates [J]. Bioconjug Chem, 2008, 19: 358-361. (Pubitemid 351213870)
20. Hamann PR, Hinman LM, Beyer CF, et al. An anti-MUC1 antibody- calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance [J]. Bioconjug Chem, 2005, 16: 346-353.
21. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies [J]. Blood, 2004, 103: 1807-1814.
22. Boghaert ER, Sridharan L, Armellino DC, et al. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl γ calicheamicin dimethyl hydrazide targets Lewis Y and eliminates Lewis Y positive human carcinoma cells and xenografts [J]. Clin Cancer Res, 2004, 10: 4538-4549.
23. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing [J]. Cancer Res, 2006, 66: 4426-4433.
24. Tassone P, Goldmacher VS, Neri P, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells [J]. Blood, 2004, 104: 3688-3696. (Pubitemid 39564446)
25. Ishitsuka K, Jimi S, Goldmacher VS, et al. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy [J]. Br J Haematol, 2008, 141: 120-131. (Pubitemid 351347531)
26. Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB [J]. Cancer Chemother Pharmacol, 2007, 60: 423-435. (Pubitemid 46944592)
27. Jeffrey SC, Andreyka JB, Bernhardt SX, et al. Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates [J]. Bioconjug Chem, 2006, 17: 831-840.
28. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometrics of drug attachment [J]. Protein Eng Des Sel, 2006, 19: 299-307. (Pubitemid 43999640)
29. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index [J]. Nat Biotechnol, 2008, 26: 925-932.
30. Feng Y, Zhen YS, Dai Y, et al. Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody [J]. Acta Pharm Sin, 2007, 42: 704-709.
31. Omelyanenko V, Kopeckova P, Gentry C, et al. HPMA copolymer-anticancer drug-OV-TL-TL16 antibody conjugates. 1. Influence of the method of synthesis on the biding affinity to OVCAR-3 ovarian carcinoma cells in vitro [J]. J Drug Target, 1993, 3: 3575-4373
32. Ulbrich K, Etrych T, Chytil P, et al. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation [J]. J Drug Target, 2004, 12: 477-489. (Pubitemid 40081303)
33. McCarron PA, Olwill SA, Marouf WMY, et al. Antibody conjugates and therapeutic strategies [J]. Mol Interv, 2005, 5: 368-380.
34. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate [J]. Clin Cancer Res, 2005, 11: 843-852.
35. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J]. Nat Biotechnol, 2003, 21: 778-784. (Pubitemid 36791396)
36. Damle NK. Antibody-drug conjugates ace the tolerability test [J]. Nat Biotechnol, 2008, 26: 884-885.